ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer.

Abstract

This study aims to investigate the association between ERCC1 codon C118T polymorphism and the response rate of platinum-based chemotherapy in patients with late-stage bladder cancer. A total of 41 eligible patients histologically confirmed as having stage IV muscle-invasive transitional cell carcinoma of the bladder were treated with platinum-based… (More)
DOI: 10.4238/gmr.15027801

Topics

3 Figures and Tables

Cite this paper

@article{Xu2016ERCC1CP, title={ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer.}, author={Z C Xu and Hong-ling Cai and Xuefeng Liu and Wanhong Xu and T. Xu and Bin Yu and Q. Zou and L Xu}, journal={Genetics and molecular research : GMR}, year={2016}, volume={15 2} }